Skip to main content
. 2023 Feb 17;48(7):991–999. doi: 10.1038/s41386-023-01540-4

Table 2.

Adverse events.

Baseline 1HR D1 D3 D7 D14 D28
Ketamine, n = 10
Vivid dreams 6 0 3 4 6 6 4
Dream-like visions 0 0 0 0 0 0 0
Blurry/double vision 2 0 2 1 3 2 1
Jerky muscle movements 1 1 2 1 3 2 1
Nausea or vomiting 3 2 0 4 2 3 1
Diarrhea 0 0 0 0 1 0 0
Hallucinations/Misperceptions 0 0 1 0 0 0 0
Larynogspasm 2 0 0 0 0 0 0
Other—Headaches 0 1 0 0 1 0 0
Other—Fatigue/Unsteadiness 0 0 2 0 0 0 0
Other—Increased thirst 0 0 1 0 0 0 0
Other—Body pain 1 1 1 1 0 0 0
Midazolam, n = 12
Vivid dreams 5 1 2 4 1 4 1
Dream-like visions 2 0 0 0 0 0 0
Blurry/double vision 1 1 1 1 0 0 0
Jerky muscle movements 0 1 1 0 0 0 0
Nausea or vomiting 2 1 3 2 2 1 1
Diarrhea 0 0 0 1 2 1 2
Hallucinations/Misperceptions 0 0 0 0 0 0 0
Larynogspasm 0 0 0 0 0 0 0
Other - Headaches 0 1 2 1 2 1 1
Other - Fatigue/Unsteadiness 1 2 3 1 0 0 0
Other - Increased thirst 0 0 0 0 0 0 0
Other - Body pain 0 0 0 0 0 0 0

Adverse event frequencies before (Baseline), just after (1 hr post-infusion), and after medication infusion on Days 1, 3, 7, 14, and 28.